

Erratum

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum

Maximilian Klingler¹, Clemens Decristoforo¹, Christine Rangger¹, Dominik Summer¹, Julie Foster², Jane K Sosabowski², Elisabeth von Guggenberg¹✉

1. Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria

2. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

✉ Corresponding author: E-mail: elisabeth.von-guggenberg@i-med.ac.at; Tel: +4351250480960; Fax: +435125046780960

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <http://ivyspring.com/terms> for full terms and conditions.

Published: 2019.06.19

Corrected article: *Theranostics* 2018; 8(11):2896-2908. doi:10.7150/thno.24378.

In our paper [1] unfortunately an error occurred in Figure 1. We therefore would like to provide the readers with the corrected figure and apologize for this inconvenience.




Figure 1: Structure of A) DOTA-MG11, B) DOTA-MGSI, C) DOTA-MGS2, D) DOTA-MGS3, E) DOTA-MGS4; R = DOTA-DGlu-Ala-Tyr-Gly.

References

- [1] Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. *Theranostics* 2018; 8(11):2896-2908.